71 results
Page 2 of 4
424B5
mec5m1b75qq kemxk03a
21 Dec 20
Prospectus supplement for primary offering
12:00am
424B5
0mfbfnlz kb
17 Dec 20
Prospectus supplement for primary offering
5:13pm
8-K
EX-1.1
rg7hbaov8 yq
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
8-K
EX-10.1
ob39c10 6l
26 Jun 20
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets
5:27pm
424B3
0cd s324hxyew14jb
15 May 20
Prospectus supplement
4:34pm
424B3
3lmz4d
15 Apr 20
Prospectus supplement
4:27pm
8-K
EX-10.1
4p6c1s2ss2phblt9ek
26 Mar 20
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
7:05am
8-K
EX-10.1
gx5pha
27 Jan 20
Entry into a Material Definitive Agreement
12:00am
CORRESP
a84kvnz
3 Oct 19
Correspondence with SEC
12:00am
8-K
EX-1.1
za2tr16esx7 hpmcn
4 Mar 19
Entry into a Material Definitive Agreement
4:15pm